Navigation Links
Neuralstem updates ALS clinical trial progress
Date:10/19/2010

ROCKVILLE, Maryland, October 18, 2010 Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first six non-ambulatory patients, the trial's Safety Monitoring Board has unanimously approved moving to the next group of ALS patients, all of whom will be ambulatory.

"We are pleased with the progress of the trial to date, and look forward to moving directly into more recently-diagnosed patients," commented Dr. Eva Feldman, PhD, MD, Principal Investigator of the trial and a consultant to Neuralstem. Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System.

"We are encouraged by the Board's approval to advance the trial to patients who have an earlier stage of the disease," said Neuralstem's CEO and president, Richard Garr. "While the primary endpoint of the trial is safety, we also hope to see some secondary endpoints showing efficacy. We are grateful to the patients, and their families, for participating in this trial."

The first six patients treated in the trial were non-ambulatory. Of these, the first three received five injections each, unilaterally, in the lumbar region of the spinal cord. The next three received ten injections each, bilaterally in the lumbar region. All of the remaining patients in the trial will be ambulatory, and therefore represent earlier stages of disease progression. Of the ambulatory group, the first three patients will receive five injections each, unilaterally, in the lumbar region. The next three will receive ten injections each, bilaterally, in the lumbar region. After the required FDA approval, the final six patients in the tri
'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Neuralstem chief scientific officer to take part in World Stem Cell Summit plenary session
2. Neuralstem stem cells survive and differentiate into neurons in rats with stroke
3. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
4. Neuralstem updates clinical trial progress
5. New "howsthepatient" iPhone App Provides a Simple, Seamless Way to Send Health Updates to Friends and Family
6. FDA Updates Import Alert 71-04 for Salmonella Contaminated Animal Feeds: Many Non-U.S. Firms Affected According to FDAImports.com, LLC
7. Clone Systems, Inc. Updates PCI Solutions for Level 1 & 2 Merchants
8. American Traveler Offers New Healthcare Jobs Hourly, Updates Via Job RSS & Twitter
9. Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates
10. Sunquest Announces Major Software Updates and Enhancements
11. New clinical trial explores role of vitamin D in preventing esophageal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Dennis Thompson ... News) -- Babies born prematurely appear to have a ... they will carry into adulthood, Swedish researchers report. ... 37 weeks, gestation have a raised risk of deep ... by blood clotting in the veins, the researchers noted ...
(Date:7/28/2014)... A new study, published in the July, 2014, ... Cancer Institute by Northwestern Medicine researchers, sheds ... growing popularity of endoscopic resection in the treatment ... the more traditional surgical resection, while more invasive, ... five-year survival rate for patients than endoscopic resection, ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A young ... to the all-too-often stories in the media today about ... occur in a matter of minutes in a hot ... to the Office of Emergency Medical Services at NHTSA. ... app for smartphones. Realizing that it’s all too easy ...
(Date:7/28/2014)... Irresistible infants have met their match with a darling ... gifting company specializes in homemade chicken noodle soup and creates bundles ... starts with home-from-the-hospital essentials every new parent will love:, ... , 6 cookies , a ladle to ... to heat and eat upon delivery, so parents can relax and ...
(Date:7/28/2014)... Albany, New York (PRWEB) July 28, 2014 ... Transparency Market Research "E-Clinical Solution Software Market- Global Industry ... 2020," the global microfluidic device market was valued at ... grow at a CAGR of 13.8% from 2014 to ... million in 2020. , Globally, the e-clinical solution software ...
Breaking Medicine News(10 mins):Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:'Precious Cargo' App Released to Help Save Babies from the Dangers of Being Accidentally Left Behind in Hot Cars 2Health News:Spoonful of Comfort Announces "New Baby" Gift Package 2Health News:Global E-Clinical Solution Software Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global E-Clinical Solution Software Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global E-Clinical Solution Software Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4
... Stereotaxis, Inc.,(Nasdaq: STXS ) today announced ... institutional investors to raise gross proceeds of $20,million through ... separate,concurrent transactions. A portion of the warrants sold will ... warrants would provide an additional,approximately $10 million in gross ...
... about possible outcomes, study finds , , MONDAY, Dec. 29 ... ill patients want doctors to frankly discuss the patient,s prognosis ... , The University of San Francisco Medical Center study, ... Journal of Respiratory and Critical Care Medicine , points out ...
... Calif., Dec. 29 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that its management is scheduled to ... in New York, on Wednesday, January 7, 2009 at ... the presentation will be available online from the investor ...
... LCAV ) Board of Directors strongly opposes the consent ... that the Company has undertaken a prudent and achievable strategic ... Joffe intervention is a poorly designed effort to take control ... Joffe effort is an undue distraction to the Company that ...
... Directory on Internet - , , ANTHEM, Ariz., ... announced launch of its new web site at http://www.mychoicedentist.com ... in the Phoenix , Arizona, area is proceeding successfully. ... Chris Theotocatos, CEO. "We anticipate expanding this service to almost ...
... Plans New Products and Expanded Services in 2009 , ... ... has reported its seventh consecutive year of revenue growth in 2008, ... demand for media relations and marketing services provided by its HRmarketer ...
Cached Medicine News:Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 2Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 3Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 4Health News:Family Needs to Know When Patient Survival Is Uncertain 2Health News:Accuray Incorporated to Present at 11th Annual Needham Growth Stock Conference 2Health News:LCA-Vision Urges Stockholders to Take No Action Regarding the Joffe Group's Threatened Consent Solicitation 2Health News:Prime Companies Announces Launch of New Dental Web Site 2Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 2Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 3
(Date:7/28/2014)... Colo. , July 28, 2014  Array ... financial results for the fourth quarter and ... a conference call to discuss those results ... Chief Executive Officer and Michael Carruthers ... call.Conference Call InformationDate:Tuesday, August 12, 2014Time:9:00 a.m. ...
(Date:7/28/2014)... 28, 2014  Syneron Medical Ltd. (NASDAQ: ... today that its new PicoWay® device has received CE ... colors and pigmented lesions on any skin type. PicoWay ... 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary PicoWay ... which are trillionths of a second, known as picosecond ...
(Date:7/28/2014)... July 28, 2014  ResMed (NYSE: RMD ... the treatment of sleep-disordered breathing and other chronic respiratory ... Germany against Taiwanese medical device manufacturer APEX ... on APEX WiZARD 210 and 220 masks.  The judgment ... Munich , is appealable, and applies throughout ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... 2011 K-V Pharmaceutical Company (the "Company") (NYSE: ... of Obstetricians and Gynecologists (ACOG) and Society for ... and ensure that healthcare providers, patients, and the ...  The information update from ACOG and SMFM confirms ...
... MONTREAL, Oct. 13, 2011 A Medco Health Solutions, ... found that 38 percent of patients prescribed Plavix® (clopidogrel)—an ... and stroke—were also using another drug that would impede ... The analysis also showed that primary care physicians ...
Cached Medicine Technology:K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 2K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 3K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 4K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 5K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 6K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 7K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 8Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 2Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 3Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 4
The all silicone construction of the shaft and neck flange provides the utmost in patient comfort. , ,The Aire-Cuf® tracheostomy tube offers a more traditional and familiar air-filled cuff desig...
... ISO termination for easy ventilator circuit attachment ... , ,Clearly the softer choice in ... ,The Portex® flexible disposable inner cannula ... chloride, providing a softer and more pliable ...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
... Adult TRACH CARE Dual Lumen, ... at the patient end of ... Double Swivel Elbow and Direction ... port. Offers multiple tracheostomy sizes, ...
Medicine Products: